The tweet was deleted by the author.
But we saved everything 🙂.
Editas Medicine announced that it will present new preclinical data on EDIT-401, its lead in vivo development candidate, at this year’s American Heart Association Scientific Sessions in Chicago.
The update signals ongoing progress in gene editing research as the company shares its latest findings from its in vivo program. Details about the preclinical data are expected to offer insights into the potential of EDIT-401 for future clinical development.
View post on X Loading...
Editas Medicine previously received clearance to begin its first clinical trial of EDIT-401 targeting hyperlipidemia patients, according to a company announcement. The company has also presented research at the ESGCT 33rd Annual Congress and participated in an investor conference, as detailed in an earlier update. These activities reflect ongoing efforts to advance and communicate its gene editing programs.